Stock Events

Stock Events

Bavarian Nordic A/S 

€26.26
0
+€0.1+0.38% Friday 19:16

Statistics

Day High
26.66
Day Low
26.18
52W High
32.76
52W Low
18.81
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q4 2025
Next
-0.2
-0.07
0.05
0.18
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BV3.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline plc is a competitor due to its involvement in the development and marketing of vaccines and pharmaceuticals, similar to Bavarian Nordic's focus areas.
Moderna
MRNA
Mkt Cap19.51B
Moderna, Inc. competes in the vaccine space, particularly in mRNA vaccines, which could overlap with Bavarian Nordic's infectious disease portfolio.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. is a direct competitor in the pharmaceutical and vaccine market, including efforts in infectious diseases that Bavarian Nordic targets.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson operates in the same pharmaceutical and vaccine sectors, making it a competitor to Bavarian Nordic, especially in the area of infectious diseases.
Sanofi
SNY
Mkt Cap116.63B
Sanofi is involved in the development of vaccines and pharmaceuticals for infectious diseases, competing with Bavarian Nordic's product offerings.
BioNTech
BNTX
Mkt Cap22.92B
BioNTech SE, known for its mRNA vaccines, competes in the vaccine market, particularly in areas that overlap with Bavarian Nordic's focus.
Novavax
NVAX
Mkt Cap1.25B
Novavax, Inc. specializes in the development of vaccines, including for COVID-19 and influenza, making it a competitor in Bavarian Nordic's market.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca PLC competes in various pharmaceutical areas, including the development of vaccines for infectious diseases, similar to Bavarian Nordic's focus.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. is a competitor due to its extensive pharmaceutical products and vaccines, including for diseases that Bavarian Nordic also targets.
Arbutus Biopharma
ABUS
Mkt Cap875.74M
Arbutus Biopharma Corporation is involved in the development of antiviral therapies and vaccines, making it a competitor in the infectious disease space targeted by Bavarian Nordic.

About

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Show more...
CEO
Dr. Paul John Chaplin MSc, Ph.D.
Employees
917
Country
Denmark
ISIN
DK0015998017

Listings

F
DE
BV3.F
MU
DE
BV3A.MU
MU
DE
BV3.MU
STU
DE
BV3.STU

0 Comments

Share your thoughts

FAQ

What is Bavarian Nordic A/S stock price today?▼
The current price of BV3.STU is €26.26 EUR — it has increased by +0.38% in the past 24 hours. Watch Bavarian Nordic A/S stock price performance more closely on the chart.
What is Bavarian Nordic A/S stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bavarian Nordic A/S stocks are traded under the ticker BV3.STU.
Is Bavarian Nordic A/S stock price growing?▼
BV3.STU stock has risen by +1.04% compared to the previous week, the month change is a +10.99% rise, over the last year Bavarian Nordic A/S has showed a +36.06% increase.
When is the next Bavarian Nordic A/S earnings date?▼
Bavarian Nordic A/S is going to release the next earnings report on May 13, 2026.
What were Bavarian Nordic A/S earnings last quarter?▼
BV3.STU earnings for the last quarter are 0.18 EUR per share, whereas the estimation was -0.2 EUR resulting in a +190.28% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Bavarian Nordic A/S have?▼
As of April 12, 2026, the company has 917 employees.
In which sector is Bavarian Nordic A/S located?▼
Bavarian Nordic A/S operates in the Health & Wellness sector.
When did Bavarian Nordic A/S complete a stock split?▼
Bavarian Nordic A/S has not had any recent stock splits.
Where is Bavarian Nordic A/S headquartered?▼
Bavarian Nordic A/S is headquartered in Hellerup, Denmark.